Dr. John Michael Kaczmar, MD

Dr. Kaczmar practices at MUSC University Hospital in Charleston, South Carolina.

Dr. Kaczmar's NPI, 1134448079, was assigned on May 18, 2010. Dr. Kaczmar holds South Carolina license 40321.

Dr. Kaczmar's primary practice is MUSC University Hospital, at 171 Ashley Ave, Charleston, SC 29425 in Charleston County. The practice phone is (843) 792-1414.

Dr. Kaczmar's primary practice is MUSC University Hospital in Charleston, South Carolina. Dr. Kaczmar is also affiliated with MUSC Health University Medical Center. The medical group on file is MUSC Health. Dmand AI also links Dr. Kaczmar to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kaczmar practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Kaczmar's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Kaczmar's licenses on file in 2 states: South Carolina and Pennsylvania.

CMS data shows 911 Medicare services from Dr. Kaczmar across 7 procedure codes in 2024, for 238 Medicare patients. Medicare paid $51,214 for them.

CMS counts 238 Medicare patients who saw Dr. Kaczmar in 2024. The largest group is 65 to 74, with 111 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kaczmar's median patient age at 69, with 25% women.

In 2024, Dr. Kaczmar wrote 600 Medicare Part D claims for 115 patients. 79% of them were for generic drugs. CMS names the drug for 451 of them, across 15 drugs with 11 or more claims each, at $696,300 in total drug cost. In 2023, CMS named 385 claims across 13 drugs.

Dr. Kaczmar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kaczmar as offering telehealth.

Dmand AI links 28 papers to Dr. Kaczmar, published from 2015 to 2025. 2020 was the busiest year, with 6. The most frequent topics are Carcinoma, Squamous Cell, Head and Neck Neoplasms and Squamous Cell Carcinoma of Head and Neck. Dr. Kaczmar has published most often in J Clin Oncol. Dr. Kaczmar's most frequent co-authors are Evan Michael Graboyes, MD, Shaun A. Nguyen, MD and Anand K. Sharma, MD.

Dmand AI links Dr. Kaczmar to 11 clinical trials, 6 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Lymphoid Interstitial Pneumonia, Head and Neck Neoplasms and Hypopharyngeal Neoplasms. National Cancer Institute (NCI) sponsors the most, 2. Open Payments lists research payments to Dr. Kaczmar that name 2 trials.

CMS Open Payments shows 57 general payments to Dr. Kaczmar from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 63% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $14,319. It also lists 60 research payments totaling $10,864 from 2021 to 2025, naming 2 clinical trials.